|
Showing 1 - 15 of
15 matches in All Departments
Preface - Notes on the Contributors - Introduction; J.Finsinger and
M.V.Pauly - GREAT BRITAIN - Regulation of the UK Insurance
Industry; J.Tapp - UNITED STATES OF AMERICA - Regulation and
Quality Competition in the US Insurance Industry; M.Pauly,
H.Kunreuther and P.Kleindorfer - GERMANY - A State Controlled
Market: The German Case; J.Finsinger - SWEDEN - The Regulation of
the Swedish Insurance Industry; K.Skogh - SWITZERLAND - Insurance
Regulation in Switzerland: An Outline with Special Reference to
Life and Motor Car Liability Insurance; C.B.Blankart and
F.Schneider - Regulation Induced Price Instability in Swiss Motor
Car Liability Insurance; C.B.Blankart and J.Finsinger - FRANCE -
The French Automobile and Life Insurance Markets; J.Finsinger and
R.Waldmann - The French Insurance Market; J-F.Outreville - CANADA -
The Economics of Life Insurance Regulation; G.F.Mathewson and
R.A.Winter - Descriptive Evidence on the Canadian Insurance
Industry; G.F.Mathewson and R.A.Winter - Index
How are the costs of health insurance premiums determined? Should
costs vary according to indicators of risk? How much do premiums
vary with risk? Do the healthy subsidize the unhealthy? Should
public subsidies vary according to economic status and risk? This
book examines these questions.
Mark V. Pauly offers a detailed look at the individual insurance
market in the United States. He explains how it works, suggests
approaches to improvement that build on what currently works well,
and provides a realistic assessment of how much improvement we can
demand and expect. He concludes that, although there are some
serious deficiencies in today's individual insurance market, there
are also some important advantages in this market that should be
preserved.
In this comprehensive volume, leading experts on health policy
consider a broad range of Medicare-related issues. They assess the
effects of Medicare policy over the last twenty years, analyze the
impact of changing economic and demographic conditions, and
consider how best to implement successful reform of the troubled
system.
What new theories, evidence, andpolicies have shaped health
economicsin the 21st century?
Editors Mark Pauly, Thomas McGuire, and Pedro Pita Barros
assemblethe expertise of leading authoritiesin this survey
ofsubstantive issues. In 16chapters theycover recent developments
in health economics, from medical spending growth to the demand for
health care, the markets for pharmaceutical products, the medical
workforce, and equity in health and health care.Its global
perspective, including an emphasis on low and middle-income
countries, will result in the same high citations that made Volume
1 (2000) a foundational text.
Presents coherent summaries of major subjects and methodologies,
marking important advances and revisions. Serves as a frequently
used non-journal reference. Introduces non-economists to the best
research in health economics. "
As Congress contemplates major revisions to America's health care
system, two leading health economists warn that significant
differences among state Medicaid programs will hinder national
health care reform. Thomas W. Grannemann and Mark V. Pauly argue
that Medicaid will need to be reformed as an early step in any
serious health care reform effort. While states such as Mississippi
and Nevada spend as little as $5,000 per poor person annually, New
York and Alaska annually spend more than $15,000 per Medicaid
patient. Large differences remain even after correcting for
cost-of-living and medical-price differences. This imbalance among
states creates an uneven and unstable foundation for any national
program to address the needs of uninsured Americans. The authors
offer principles for reform designed to encourage equity,
efficiency, and accountability in all publicly funded health care
programs. They suggest changes in provider payment methods and
federal/state financing designed to promote interstate equity,
equality of payment across settings, claims-based accountability,
provider network control, and value-based cost containment. Such
reform will require upfront changes in Medicaid to improve access
to high-value health care for low-income persons (particularly
those in low-Medicaid-benefit states) and to help slow the rate of
growth in medical costs. These changes will level the playing field
for state programs and provide a crucial foundation for further
national reform.
Insurance Decision Making and Market Behavior discusses such
behavior with the intent of categorizing these insurance
"anomalies". It represents a first step in constructing a theory of
insurance decision making to explain behavior that does not conform
to standard economic models of choice and decision-making. Finally,
the authors propose a set of prescriptive solutions for improving
insurance decision-making. Considerable evidence suggests that many
people for whom insurance is worth purchasing do not have coverage
and others who appear not to need financial protection against
certain events actually have purchased coverage. There are certain
types of events for which one might expect to see insurance widely
marketed are now viewed today by insurers as uninsurable and there
are other policies one might not expect to be successfully marketed
that exist on a relatively large scale. In addition, evidence
suggests that cost-effective preventive measures are sometimes
rewarded by insurers in ways that could change their clients'
behavior. These examples reveal that insurance purchasing and
marketing activities do not always produce results that are in the
best interest of individuals at risk. Insurance Decision Making and
Market Behavior discusses such behavior with the intent of
categorizing these insurance "anomalies". It represents a first
step in constructing a theory of insurance decision making to
explain behavior that does not conform to standard economic models
of choice and decision-making. Finally, the authors propose a set
of prescriptive solutions for improving insurance decision-making.
Despite rising real incomes, the number of uninsured American
workers and their dependents has not fallen appreciably.
Policymakers in both political parties have considered the use of
tax credits to encourage the purchase of private insurance
coverage. This study analyzes the effects of a variety of forms of
tax credits, especially for workers whose incomes place them above
the poverty line but below the median family income -- a group in
which the vast majority of the uninsured are to be found. The
authors' conclusions differ from more conventional analyses in two
ways. First, they find plausible effects on the numbers of
uninsured persons that are larger than those of other studies.
Second, they explore the distinction between the "cost" to the
federal government of tax credits and the more relevant measures of
tax credits' effects on aggregate economic welfare and cost to the
economy. Nevertheless, they still find, as do most other analysts,
that modest subvsidies will have little effect in reducing the
number of the uninsured. For a given amount "spent" on credits, a
key tradeoff exists between the breadth of the reduction in the
uninsured and the depth of the increase in the coverage they take.
While it is unlikely that the number of uninsured will ever be
literally zero, the authors believe that carefully designed tax
credits can both reduce the numbers of uninsured and improve the
equity of tax treatment of the insured.
The 1990s saw no progress in the financing of health care. About 40
million Americans still have no health insurance including 22
percent of America's children and 19 percent of young adults. And
an economic downturn brings with it increased numbers of uninsured.
What can be done? Mark V. Pauly and John S. Hoff answer with a tax
credit/voucher system introduced in a common-sense way, with as
much simplicity and flexibility as possible. The United States can
launch such a program immediately and make needed adjustments along
the way. The use of the credit assists people in obtaining
insurance and provides tax equity. The authors chronicle changes in
U.S. attitudes about health care and in the economic environment,
tackle design issues, and consider policy trade-offs and problems
of the technicalities of such a program. They offer a sample
tax-credit plan and respond to possible objections to their plan.
In this book, distinguished scholars Philip A. Rea, Mark V. Pauly,
and Lawton R. Burns explore the science and management behind
marketable biomedical innovations. They look at how the science
actually played out through the interplay of personalities, the
cultures within and between academic and corporate entities, and
the significance of serendipity not as a mysterious phenomenon but
one intrinsic to the successes and failures of the experimental
approach. With newly aggregated data and case studies, they
consider the fundamental economic underpinnings of investor-driven
discovery management, not as an obstacle or deficiency as its
critics would contend or as something beyond reproach as some of
its proponents might claim, but as the only means by which
scientists and managers can navigate the unknowable to discover new
products and decide how to sell them so as to maximize the
likelihood of establishing a sustainable pipeline for still more
marketable biomedical innovations.
In this book, distinguished scholars Philip A. Rea, Mark V. Pauly,
and Lawton R. Burns explore the science and management behind
marketable biomedical innovations. They look at how the science
actually played out through the interplay of personalities, the
cultures within and between academic and corporate entities, and
the significance of serendipity not as a mysterious phenomenon but
one intrinsic to the successes and failures of the experimental
approach. With newly aggregated data and case studies, they
consider the fundamental economic underpinnings of investor-driven
discovery management, not as an obstacle or deficiency as its
critics would contend or as something beyond reproach as some of
its proponents might claim, but as the only means by which
scientists and managers can navigate the unknowable to discover new
products and decide how to sell them so as to maximize the
likelihood of establishing a sustainable pipeline for still more
marketable biomedical innovations.
Insurance is an extraordinarily useful tool to manage risk. When it
works as intended, it provides financial protection to individuals
and a profitable business model for insurance firms and their
investors. But it is broadly misunderstood by consumers,
regulators, and insurance executives. This book looks at the
behavior of individuals at risk, insurance industry decision
makers, and policy makers at the local, state, and federal level
involved in the selling, buying, and regulating of insurance. It
compares their actions to those predicted by benchmark models of
choice derived from classical economic theory. When actual choices
stray from predictions, the behavior is considered to be anomalous.
With considerable sums of money at stake, both in consumer premiums
and insurance company payouts, it is important to understand the
reasons for anomalous behavior. Howard Kunreuther, Mark Pauly, and
Stacey McMorrow examine these anomalies through the lens of
behavioral economics, which takes into account emotions, biases,
and simplified decision rules. The authors then consider if and how
such behavioral anomalies could be modified to improve individual
and social welfare. This book is neither a defense of the insurance
industry nor an attack on it. Neither is it a consumer guide to
purchasing insurance, although the authors believe that consumers
will benefit from the insights it contains. Rather, this book
describes situations in which both public policy and the insurance
industry s collective posture need to change. This may require
incentives, rules, and institutions to help reduce both inefficient
and anomalous behavior, thereby encouraging behavior that will
improve individual and social welfare.
Insurance is an extraordinarily useful tool to manage risk. When it
works as intended, it provides financial protection to individuals
and a profitable business model for insurance firms and their
investors. But it is broadly misunderstood by consumers,
regulators, and insurance executives. This book looks at the
behavior of individuals at risk, insurance industry decision
makers, and policy makers at the local, state, and federal level
involved in the selling, buying, and regulating of insurance. It
compares their actions to those predicted by benchmark models of
choice derived from classical economic theory. When actual choices
stray from predictions, the behavior is considered to be anomalous.
With considerable sums of money at stake, both in consumer premiums
and insurance company payouts, it is important to understand the
reasons for anomalous behavior. Howard Kunreuther, Mark Pauly, and
Stacey McMorrow examine these anomalies through the lens of
behavioral economics, which takes into account emotions, biases,
and simplified decision rules. The authors then consider if and how
such behavioral anomalies could be modified to improve individual
and social welfare. This book is neither a defense of the insurance
industry nor an attack on it. Neither is it a consumer guide to
purchasing insurance, although the authors believe that consumers
will benefit from the insights it contains. Rather, this book
describes situations in which both public policy and the insurance
industry s collective posture need to change. This may require
incentives, rules, and institutions to help reduce both inefficient
and anomalous behavior, thereby encouraging behavior that will
improve individual and social welfare."
The majority of Americans receive their health insurance for
themselves and their families through their job. The employee pays
a portion of the premium but the employer chooses the type and
amount of coverage offered as well as administers the plan. This
book addresses the question: Who really pays for employer-arranged
health insurance? Are premiums paid from company profits or do
employees bear the cost through lower wages? Pauly suggests that
this confusion has complicated the debate on public policy and
needs to be alleviated.
This work first shows how views taken by business and political
leaders during the Clinton health reform proposal debate were
affected by this confusion and did not follow the economic view. It
then provides a novel, intuitive, but comprehensive outline of the
economic theory that bears on this question. Empirical evidence
consistent with the economic view is summarized, and the
implications of the view for some important issues in health policy
and in practical health benefits management are discussed in
detail.
"Health Benefits at Work" explores the political economy of health
policy when the stakeholders have an uncertain and possibly
incorrect understanding of their actual interests. For the benefits
specialist, it provides an accessible treatment of the complex and
often counterintuitive economics of health benefits. This will
appeal to the health policy community as well as economists and
anyone concerned with issues surrounding health insurance in
employment settings.
"This book is refreshing . . . clean and intuitive; the logic
devastating." --Michael A. Morrissey
Mark V. Pauly is Professor of Health Care Systems and Insurance and
RiskManagement, The Wharton School, University of Pennsylvania.
|
You may like...
Hampstead
Diane Keaton, Brendan Gleeson, …
DVD
R66
Discovery Miles 660
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|